Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira Receives Green Light for Phase I Ebola Study

Premium

Tekmira Pharmaceuticals said this week that it has received clearance from the US Food and Drug Administration to begin phase I testing of an improved formulation of its RNAi-based Ebola virus drug TKM-Ebola.

The company now expects to begin dosing healthy volunteers in the study early next year.

The company is developing the drug under a contract from the US Department of Defense that could be worth up to $140 million and fund the drug's development through to commercialization. Tekmira had previously tested an earlier version in phase I, but cut that trial short in order to incorporate improvements to its lipid nanoparticle delivery vehicles.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.